Likely new treatment target identified for diabetic retinopathy

October 10, 2017
In oxygen-compromising conditions like diabetes, the body grows new blood vessels to help, but the result is often leaky, dysfunctional vessels that make bad matters worse. Credit: Phil Jones, Senior Photographer, Augusta University

In oxygen-compromising conditions like diabetes, the body grows new blood vessels to help, but the result is often leaky, dysfunctional vessels that make bad matters worse.

Now scientists have identified a new target for reducing that dysfunctional blood vessel development in the eye in a common condition called , the leading cause of blindness in working-age adults.

"If we block the receptor A2a, the blood vessels will not leak and not as many new blood vessels will grow," says Dr. Yuqing Huo, chief of the Vascular Inflammation Program at the Vascular Biology Center at the Medical College of Georgia at Augusta University.

An inhibitor of adenosine receptor A2a already is in clinical trials for Parkinson's disease.

Adenosine is a natural structural component of basic body essentials like DNA and RNA as well as the ubiquitous cell fuel ATP. It can help blood vessels expand, battle bad heart rhythms and even provide pain relief. Its family of includes adenosine receptor A2a, which is important for the retina and found on the endothelial cells that line blood vessels, says Huo, co-corresponding author of the study in the journal Nature Communications.

When are good, their expression is low in endothelial cells. But in diabetes, where oxygen levels go down, adenosine A2a receptor expression goes way up and a vicious cycle is born.

Endothelial cells that line the blood vessels of the retina begin to shrink, even disappear in diabetes. Expression of adenosine receptor A2a increases, apparently to enable endothelial cells to take up more glucose that can be converted to energy to help restore good oxygen and blood flow. In this case, that means repairing existing blood vessels and growing new ones in a process called angiogenesis. But in a scenario where the cells don't use energy efficiently or build blood vessels well it's actually called "pathological angiogenesis." Old and new blood vessels alike readily bleed or contract, leading to hemorrhage and/or retinal detachment and blindness, the scientists write.

"They grow too much, too fast," Huo says. It's not yet clear whether it's the high glucose levels of diabetes and/or the resulting inflammation or other factors that increase expression of adenosine receptor A2a. Huo notes that adenosine's many actions include an anti-inflammatory effect.

But the work of Huo and his colleagues indicates that however it happens adenosine receptor A2a's higher profile role in this scenario makes it a likely treatment target.

A key problem appears to be that the receptor aids the inefficiency of endothelial cells. These cells generate about 85 percent of their fuel through glycolysis, a way to convert glucose to the cell fuel ATP without using oxygen. Even with plenty of oxygen handy, endothelial cells appear to like this method. By comparison, cellular respiration, which requires oxygen, produces nearly 40 molecules of ATP per molecule of glucose versus only about two ATP molecules per glucose molecule with glycolysis.

When the scientists activate the receptor, it promotes the enzymes that promote glycolysis. Increased use of this inefficient energy production process of glycolysis has been shown to occur in endothelial cells in people with proliferative diabetic retinopathy.

Conversely, when the scientists knocked out or deleted adenosine receptor A2a from endothelial cells, it decreased glycolysis. Blocking glycolysis, in turn, dramatically inhibited blood vessel proliferation and sprouting of that overexpress the receptor.

When oxygen levels were more normal, knocking out or deleting adenosine receptor A2a didn't seem to have that much impact on glycolysis, possibly because the receptor's expression is not that high when oxygen levels are normal, the scientists suspect.

All the reciprocal cause and effect they found supports the new idea that the receptor promotes glycolysis, which promotes pathological angiogenesis in retinopathies, Huo says.

Much work remains. For example, they have not yet figured out the connection between the adenosine receptor A2a and VEGF receptors, but there has to be some synergy, Huo says, since as its name implies, vascular endothelial growth factor, or VEGF, also is clearly important to endothelial cell repair and new blood formation.

In the right environment, adenosine A2a receptor has a positive role in as well: activation of the receptor in a mouse model of wound healing shows increased activation of healthy angiogenesis that aids recovery.

His lab also wants to try in their animal models and human retinal tissue, the adenosine receptor A2a inhibitor showing success and safety in patients with Parkinson's disease. In Parkinson's, expression of adenosine receptor A2a goes up in a part of the brain involved with voluntary movement.

Inhibitors under study for that degenerative condition appear to decrease uncontrolled movement and generally slow disease progression without significant side effects, Huo says.

It's the safety and effectiveness in that condition combined with his findings in the retina, that have Huo planning to use existing inhibitors in his studies. He's also working with co-corresponding author and chemist, Dr. Mei Hong, of the Drug Discovery Center, Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, to develop another adenosine receptor A2a inhibitor.

Endothelial likely opt to use glycolysis because during development, many are formed in a hypoxic, or no oxygen, environment, Huo notes. Many other cell types only turn to glycolysis when they are stressed. He adds that caffeine is a not-very-specific blocker of adenosine receptor A2a.

Nearly 10 percent of Americans have diabetes, according to the American Diabetes Association. Up to 45 percent of those individuals have some degree of diabetic retinopathy, according to the National Eye Institute.

The retina is inside the back of the eye, a multi-layered and vascular tissue, which receives light and transforms it to a neural impulse that goes to the brain. The optic nerve that transmits the neural impulses is in the center of the retina, and the retina's major blood vessels radiate from the optic nerve.

In addition to efforts to better manage blood glucose and blood pressure levels, current therapies for diabetic retinopathy include laser surgery to attempt to seal leaky as well as surgery to remove vitreous gel, and scar tissue to better enable light to again focus on the retina. Direct injections into the eye of steroids may help with swelling and an anti-VEGF treatment may help reduce growth of the leaky vessels.

Explore further: Study identifies blood vessel as a therapeutic target for diabetes

Related Stories

Study identifies blood vessel as a therapeutic target for diabetes

September 14, 2017
Blood vessels have an often overlooked role of regulating the transfer of nutrients from the blood to organs in the body. In a new Yale-led study, researchers have identified a role of a secreted protein, apelin, in regulating ...

Powerful anti-inflammatory molecule may block vision loss in diabetic retinopathy

January 3, 2017
A more powerful version of an anti-inflammatory molecule already circulating in our blood may help protect our vision in the face of diabetes.

How blood vessels are formed

September 15, 2017
Researchers at Heidelberg University have discovered a crucial biological step that regulates the formation of blood vessels. They were able to show that the proteins YAP and TAZ play an important role in this process. The ...

How blood vessels slow down and accelerate tumor growth

July 18, 2017
Cancer cells have an enormous need for oxygen and nutrients. Therefore, growing tumors rely on the simultaneous growth of capillaries, the fine branching blood vessels that form their supply network. The formation of new ...

New target for the fight against cancer as a result of excessive blood vessel formation

August 1, 2013
New blood vessel formation (angiogenesis) stimulates the growth of cancer and other diseases. Anti-angiogenic inhibitors slow down cancer growth by disrupting the blood supply to the tumor. To date, the success of these treatments ...

Genome editing with CRISPR-Cas9 prevents angiogenesis of the retina

July 24, 2017
A research team from the Schepens Eye Research Institute of Massachusetts Eye and Ear has successfully prevented mice from developing angiogenesis of the retina—the sensory tissue at the back of the eye—using gene-editing ...

Recommended for you

Diabetes pill might replace injection to control blood sugar

October 17, 2017
(HealthDay)— An injectable class of diabetes medication—called glucagon-like peptide-1 or GLP-1—might one day be available in pill form, research suggests.

Skimping on sleep may contribute to gestational diabetes

October 17, 2017
The amount of time spent sleeping in the United States has dropped significantly in the past twenty years with almost a quarter of women and 16 percent of men experiencing insufficient sleep. Now, a new study has found that ...

Artificial pancreas performs well in clinical trial

October 16, 2017
During more than 60,000 hours of combined use of a novel artificial pancreas system, participants in a 12-week, multi-site clinical trial showed significant improvements in two key measures of well-being in people living ...

Omega-6 fats may help prevent type 2 diabetes

October 11, 2017
The risk of developing type 2 diabetes could be significantly reduced by eating a diet rich in omega-6 polyunsaturated fats, a new study suggests.

Where there's type 1 diabetes, celiac disease may follow

October 10, 2017
(HealthDay)—Parents of young children with type 1 diabetes need to be on the lookout for symptoms of another autoimmune condition—celiac disease, new research suggests.

Type 1 diabetes and the microbiota—MAIT cells as biomarkers and new therapeutic targets

October 10, 2017
Together with colleagues from AP-HP Necker–Enfants Malades Hospital in Paris, scientists from the Cochin Institute (CNRS / INSERM / Paris Descartes University) have discovered that the onset of type 1 diabetes is preceded ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.